CAR-T therapy modifies T cells to express synthetic antigen-binding receptors that can directly recognize tumor surface antigens without the need for MHC presentation, broadening their applicability to tumors with low MHC expression [151]. The gene discussed is HLA-C; the disease is neoplasm.